Merck (MRK) Q1 2026 Earnings Call Transcript

Merck reported Q1 revenue of $16.3 billion, up 5% year over year, led by 8% growth in KEYTRUDA family sales to $8.0 billion and 6% growth in animal health. Management narrowed and raised 2026 guidance to $65.8 billion-$67.0 billion in revenue and $5.04-$5.16 in non-GAAP EPS, despite a $9 billion Cidara acquisition charge that drove a $1.28 per-share loss for the quarter. The company also highlighted multiple regulatory milestones, over 20 new product launches, a $3 billion buyback plan, and AI partnerships with Google Cloud, Tempus AI, and Mayo Clinic.

Analysis

Merck is trying to re-rate from a single-asset oncology story into a multi-platform growth engine, and the market should care less about near-term GAAP noise than about the slope of the launch curve. The key second-order effect is that the company is now stacking multiple commercial ramps at once—respiratory, pneumococcal, HIV, cardiovascular, and oncology—so the earnings mix should become less binary as KEYTRUDA growth normalizes. That diversification matters because it reduces the valuation discount usually applied to patent-cliff-biased large pharma, even if headline growth still looks modest this year.

The biggest hidden issue is not the one-time charges; it is execution risk across a much wider operating surface area. A broad launch portfolio means field force distraction, reimbursement complexity, and inventory normalization can all depress realized sales for several quarters even when underlying demand is healthy. The management commentary on timing noise suggests investors will likely see choppy reported growth through 2H26, which can create entry points if the Street over-penalizes transient quarter-to-quarter volatility.

On the pipeline, the market may be underestimating how much optionality is embedded in the next 6-12 months of readouts versus the more obvious KEYTRUDA franchise. The real inflection is whether Merck can prove that its newer assets are not just scientifically credible but commercially scalable outside of oncology; if even one of the cardiometabolic or respiratory programs becomes a differentiated standard of care, the stock’s multiple should expand. Conversely, if the upcoming data disappoint or commercialization stalls, the current strategy shifts from “diversified growth” to “expensive pipeline accumulation,” which would pressure sentiment despite the raised guidance.

Key Decisions for Investors

• Long MRK on a 3-6 month horizon; use post-earnings weakness as the entry window. Risk/reward favors upside if the market starts capitalizing the launch portfolio instead of the legacy KEYTRUDA trajectory.
• Pair trade: long MRK / short a more single-asset oncology large-cap, on the thesis that Merck’s breadth lowers terminal concentration risk while still preserving pipeline upside. Cover if near-term launch execution falters or if follow-on data miss.
• Sell out-of-the-money MRK puts into volatility over the next 30-60 days to express a constructive but patient view. The one-time charges and guidance optics should keep implied vol elevated relative to fundamental downside.
• If MRK rallies into the August bladder cancer decision, consider trimming 25-30% of the long and re-adding only if approval lands with favorable label breadth. The catalyst is real, but expectations can run ahead of label economics.
• Add TEM on pullbacks as a beneficiary of deeper pharma-AI commercialization partnerships, but size it as a venture-style satellite position. The upside is strategic adoption, while the main risk is that these agreements remain non-exclusive and slow to monetization.